Audentes Therapeutics Inc (NASDAQ:BOLD) – Analysts at William Blair issued their Q1 2019 earnings per share estimates for shares of Audentes Therapeutics in a research note issued to investors on Friday. William Blair analyst R. Prasad anticipates that the biotechnology company will post earnings of ($0.94) per share for the quarter. William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Audentes Therapeutics’ Q2 2019 earnings at ($0.97) EPS and Q4 2019 earnings at ($0.89) EPS.
Audentes Therapeutics (NASDAQ:BOLD) last announced its earnings results on Thursday, March 8th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.09.
Shares of Audentes Therapeutics (NASDAQ:BOLD) opened at $36.24 on Monday. The stock has a market capitalization of $1,321.59, a P/E ratio of -10.66 and a beta of 0.89. Audentes Therapeutics has a 12-month low of $13.90 and a 12-month high of $41.80.
In other news, Director Louis G. Lange sold 18,000 shares of the stock in a transaction that occurred on Friday, December 22nd. The stock was sold at an average price of $30.88, for a total value of $555,840.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Orbimed Advisors Llc sold 433,210 shares of the stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $35.11, for a total value of $15,210,003.10. The disclosure for this sale can be found here. Insiders sold 872,848 shares of company stock valued at $30,594,852 over the last three months. 47.30% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of BOLD. SG Americas Securities LLC acquired a new position in shares of Audentes Therapeutics in the third quarter valued at $143,000. Teacher Retirement System of Texas acquired a new position in shares of Audentes Therapeutics in the fourth quarter valued at $208,000. MetLife Investment Advisors LLC acquired a new position in shares of Audentes Therapeutics in the fourth quarter valued at $248,000. Nationwide Fund Advisors raised its stake in shares of Audentes Therapeutics by 288.9% in the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 6,384 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in shares of Audentes Therapeutics in the third quarter valued at $295,000. 67.35% of the stock is owned by institutional investors.
WARNING: “Audentes Therapeutics Inc to Post Q1 2019 Earnings of ($0.94) Per Share, William Blair Forecasts (BOLD)” was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3256999/audentes-therapeutics-inc-to-post-q1-2019-earnings-of-0-94-per-share-william-blair-forecasts-bold.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.